Article | May 1, 2023

Increase Collaboration In Customer-Supplier Relationships To Overcome Supply Chain Limitations

By Brian Crawford, VP of Operations at Asahi Kasei Bioprocess America

Supply Chain

As demand begins to level out in the aftermath of the COVID-19 pandemic, drug manufacturers and suppliers are collaborating to build a new set of standard operating procedures across the industry. The pandemic had a widespread and well-known impact on raw materials and labor that delayed supply chains globally. In the bioprocessing industry, companies fast-tracked projects to help combat the pandemic; as a result, demand for single-use components skyrocketed as raw materials and labor forces dwindled.

It is crucial to reframe expectations from how the supply chain existed pre-pandemic to how it will function going forward. Just-in-time manufacturing strategies are no longer suitable for maintaining efficient, reliable timelines; instead, suppliers must consider holding higher levels of inventory and increasing production capacity. Download the full article to learn more about how customers, suppliers, and sub-suppliers are utilizing enhanced forecasting and collective problem-solving efforts to prepare adaptive supply chain strategies.

access the Article!

Get unlimited access to:

Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue. X

Enter your credentials below to log in. Not yet a member of Pharmaceutical Online? Subscribe today.

Subscribe to Pharmaceutical Online X

Please enter your email address and create a password to access the full content, Or log in to your account to continue.


Subscribe to Pharmaceutical Online